As antigenic drift continues to challenge seasonal flu vaccines, 2026 heralds a new era with universal breakthroughs—from mRNA platforms targeting conserved epitopes to nanoparticle shields offering broad protection—poised to end the annual reformulation cycle and fortify global defenses.
Read More